Biotechnology Research Data Governance Law In Russia.
1. Introduction
Biotechnology Research Data Governance Law in Russia concerns the legal rules governing the collection, processing, storage, analysis, sharing, transfer, publication and destruction of information generated through biotechnology and biomedical research.
Biotechnology research frequently involves highly sensitive information, including:
Human genetic and genomic information.
DNA and RNA sequencing results.
Biological samples and tissue information.
Clinical-trial and laboratory research data.
Patient health records.
Reproductive and hereditary information.
Population-genetics and immunological research.
Biometric and molecular identification information.
Artificial intelligence-generated biomedical datasets.
Russia regulates these activities through a combination of personal-data legislation, healthcare legislation, genetic-engineering legislation, scientific-research legislation and biological-security regulations.
An especially important development is Federal Law No. 43-FZ of 20 February 2026, which introduced specific restrictions on transferring human genetic data obtained through population genetic and immunological research. These provisions took effect on 1 September 2026. Consequently, they are applicable as of November 2026.
ГАРАНТ+1
The central legal objective is to balance scientific development, individual privacy, medical confidentiality, national biological security and international scientific cooperation.
2. Constitutional foundations of biotechnology research data governance
The Russian Constitution provides the fundamental legal foundation for protecting information generated through biotechnology research.
Article 23 – Right to privacy
Article 23 protects private life, personal and family secrets, and confidentiality of communications.
This protection is relevant when biotechnology researchers collect genetic information, hereditary characteristics, reproductive information or identifiable medical records.
Article 24 – Restrictions on collecting and disseminating personal information
Article 24 establishes constitutional restrictions on collecting, storing, using and disseminating information about an individual's private life without lawful justification or consent.
For biotechnology institutions, this means that personal information cannot be treated as an unrestricted scientific resource.
Article 41 – Right to health protection
Article 41 recognizes the right to health protection and medical assistance.
It supports the development of biomedical research while requiring appropriate protection of research participants.
Article 44 – Freedom of scientific and other creative activity
Article 44 protects scientific creativity and intellectual activity.
Biotechnology researchers therefore operate within a constitutional framework that protects scientific research but does not eliminate privacy and confidentiality obligations.
Legal interpretation: Scientific freedom does not automatically authorize unrestricted access to human genetic information. Researchers must comply with applicable data-protection, medical-confidentiality and biosafety requirements.
3. Principal legislation governing biotechnology research data
Russia does not have one comprehensive statute covering every aspect of biotechnology research data governance. Instead, several federal laws operate together.
| Legislation | Importance |
|---|---|
| Federal Law No. 152-FZ of 2006 | Personal-data protection |
| Federal Law No. 86-FZ of 1996 | Genetic-engineering activities and human genetic-data transfers |
| Federal Law No. 323-FZ of 2011 | Healthcare and medical confidentiality |
| Federal Law No. 127-FZ of 1996 | Scientific and technological research |
| Federal Law No. 61-FZ of 2010 | Medicinal products and pharmaceutical research |
| Federal Law No. 180-FZ of 2016 | Biomedical cellular products |
| Federal Law No. 492-FZ of 2020 | Biological safety |
These laws should be interpreted together, particularly when a research project involves identifiable human genetic information.
Минтруд России+2
4. Personal data protection under Federal Law No. 152-FZ
Federal Law No. 152-FZ – On Personal Data
The Personal Data Law is one of the most important legal instruments governing biotechnology research datasets.
It regulates the processing of personal information by public authorities, universities, research institutions, hospitals, pharmaceutical companies and private biotechnology organisations.
A. Classification of research information
Biotechnology research data may fall into several legal categories.
1. Ordinary personal data
Examples include:
Name and address.
Contact information.
Research participant identification numbers.
Employment and educational details.
2. Special categories of personal data
Article 10 covers sensitive information, including:
Health information.
Racial and ethnic origin.
Political views.
Religious or philosophical beliefs.
Information concerning intimate life.
Consequently, identifiable clinical research information generally requires particularly careful legal treatment.
3. Biometric personal data
Article 11 regulates biometric information used by an operator to establish an individual's identity.
DNA information is not automatically classified as biometric personal data in every circumstance merely because it is genetic. Its classification depends on the statutory definition and how the information is used.
B. Consent requirements
Article 9 establishes consent requirements for personal-data processing.
For research institutions, consent documentation should clearly identify:
The categories of information being collected.
The purpose of the research.
The intended processing activities.
The persons or organisations receiving the data.
The applicable retention period.
The conditions for withdrawal or other exercise of data-subject rights.
Where Article 10 applies, its specific written-consent requirements and statutory exceptions must also be considered.
C. Scientific and statistical research exemption
Russian law permits certain processing activities for statistical or research purposes, subject to legal conditions.
Article 6(1)(9) is particularly relevant to processing for statistical or other research purposes where personal data are anonymised.
Article 10 also contains specific exceptions concerning scientific, statistical and other legally permitted processing of sensitive categories.
This is not a blanket exemption for biotechnology companies.
An institution cannot simply describe a project as scientific research to avoid privacy obligations.
Минтруд России+1
5. Special regulation of human genetic research data
One of the most significant developments in Russian biotechnology law concerns the protection and transfer of human genetic data.
Federal Law No. 86-FZ of 5 July 1996
The Federal Law on State Regulation in the Field of Genetic Engineering traditionally focused on genetic-engineering activities.
However, Federal Law No. 43-FZ of 20 February 2026 expanded this framework by introducing provisions specifically addressing human genetic data.
The amendments define human genetic data as information about nucleotide sequences in nucleic-acid polymers and their chemical modifications, obtained through molecular-genetic examination of human biological material.
They also define population genetic and immunological research as research involving groups of more than three individuals selected from a population and associated through common characteristics.
A. Article 13.1 – Transfer of human genetic data outside Russia
Article 13.1 identifies the permitted purposes for transferring human genetic data outside Russian territory.
These include:
Providing medical assistance to a particular patient.
Developing and manufacturing medicinal products or biomedical cellular products for a particular patient.
Conducting international cooperation in accordance with Russian law.
The transfer must follow the applicable governmental procedure.
B. Article 13.2 – Population genetic and immunological research
Article 13.2 establishes a particularly significant restriction.
It generally prohibits transferring human genetic data obtained through population genetic or immunological research to specified foreign persons and organisations, including foreign entities operating within Russia and persons or organisations located outside Russia.
Exceptions are possible in accordance with the statutory procedure.
Importantly, the law defines transfer broadly. It includes:
Collection.
Storage.
Providing access.
Sending or transmitting information.
Distribution.
Publication or placement on information networks.
Other actions that make the data available to the specified foreign recipients.
Therefore, merely storing research data on a foreign-controlled platform or providing remote access may raise legal questions even when no physical biological sample leaves Russia.
ГАРАНТ+1
6. Government Regulation No. 750 of 15 June 2026
Applicable from 1 September 2026
The Russian Government adopted Regulation No. 750 on 15 June 2026 to establish procedures for transferring human genetic data outside Russia.
This regulation is particularly important because it implements Articles 13.1 and 13.2 of Federal Law No. 86-FZ.
A. Interdepartmental Commission
The regulation establishes an Interdepartmental Commission responsible for considering applications involving the transfer of human genetic data outside Russia.
The Commission examines whether a proposed transfer satisfies the applicable legal requirements.
B. Approval procedure
In cases requiring approval, the applicant must obtain a decision from the Commission before transferring the relevant genetic information.
The Commission generally has 15 working days to consider an application.
It may request additional information within the prescribed procedure.
C. Grounds for refusal
The Commission may refuse permission where:
The application contains incomplete information.
The information submitted is unreliable.
The transfer creates risks to the rights and legitimate interests of Russian citizens.
The transfer creates risks to Russia's biological security.
D. Publication of aggregated research results
The regulation distinguishes between transferring identifiable or underlying genetic datasets and publishing aggregated scientific results.
Certain publications containing only aggregated indicators, integrated statistics or mathematical and statistical models may be transmitted following notification to the Commission.
The relevant material must not contain genetic data relating to identifiable individual persons.
E. Anonymisation requirements
The regulation requires genetic information transmitted under specified exceptional or publication-related routes to be presented in anonymised form.
Researchers must therefore distinguish between:
Raw genetic sequencing information.
Identifiable genetic datasets.
Pseudonymised datasets.
Properly anonymised statistical information.
Aggregated population-level research findings.
Pseudonymisation should not automatically be treated as equivalent to anonymisation.
ГАРАНТ
7. Medical confidentiality under Federal Law No. 323-FZ
The Federal Law No. 323-FZ, On the Fundamentals of Health Protection of Citizens in the Russian Federation, is another important component of biotechnology data governance.
Article 13 – Medical confidentiality
Article 13 protects information constituting medical confidentiality.
This includes information concerning:
Medical consultations.
Health conditions.
Diagnoses.
Medical examinations.
Treatment.
Other information obtained through medical intervention.
Biotechnology research institutions that receive patient information from hospitals must consider these confidentiality requirements.
Article 20 – Informed voluntary consent
Article 20 regulates informed voluntary consent to medical intervention.
When research involves medical intervention, researchers must distinguish between consent to medical treatment and consent to the processing or further disclosure of research data.
One form of consent should not automatically be interpreted as authorisation for every subsequent use of the information.
Practical implications
A biotechnology research institution should establish:
Confidentiality agreements with researchers.
Restricted access to clinical datasets.
Procedures for handling research participants' records.
Appropriate consent documentation.
Rules governing disclosure to third parties.
Procedures for responding to unauthorised access.
8. Data localisation and cross-border research cooperation
Russia's personal-data localisation requirements are particularly relevant to multinational biotechnology research.
Under Article 18(5) of Federal Law No. 152-FZ, as amended by Federal Law No. 23-FZ of 28 February 2025, the collection of personal data of Russian citizens generally requires specified recording, systematisation, accumulation, storage, updating and extraction operations to use databases located in Russia, subject to statutory exceptions.
The amended provision took effect on 1 July 2025.
Article 12 separately regulates cross-border transfers of personal data.
Following the 2022 amendments, operators generally have to notify Roskomnadzor of their intention to conduct cross-border transfers, subject to the applicable statutory procedure.
The 2026 amendments to Article 12 under Federal Law No. 265-FZ introduced further changes to the system for identifying countries that provide adequate personal-data protection.
Consultant Plus+2
Important distinction: Compliance with Article 12 of the Personal Data Law does not automatically authorise a transfer prohibited or restricted by Articles 13.1 and 13.2 of the Genetic Engineering Law.
A biotechnology company conducting international genomic research must examine both legal frameworks.
9. Regulation of clinical-trial and pharmaceutical research data
Federal Law No. 61-FZ of 12 April 2010, On the Circulation of Medicines, governs medicinal-product development, clinical research and related regulatory activities.
Biotechnology companies developing:
Gene therapies.
Recombinant proteins.
Biological medicines.
Vaccines.
Advanced therapeutic products.
must comply with applicable pharmaceutical research and registration requirements.
Clinical-trial data should be sufficiently reliable to demonstrate the safety and effectiveness of the investigated medicinal product.
Research institutions must also maintain appropriate documentation concerning:
Trial participants.
Clinical observations.
Adverse events.
Laboratory results.
Research methodology.
Data integrity.
Statistical analysis.
Regulatory submissions.
Where clinical-trial data contain identifiable health information or genetic information, the relevant personal-data and medical-confidentiality provisions apply as well.
10. Biomedical cellular-product research data
Federal Law No. 180-FZ of 23 June 2016, On Biomedical Cellular Products, is important for research involving human cells and cellular technologies.
Its regulatory framework concerns the development, manufacture, quality, safety and circulation of biomedical cellular products.
Relevant research information can include:
Cell-source information.
Donor-related information.
Cellular characteristics.
Manufacturing records.
Quality-control results.
Product safety information.
Clinical investigation data.
Research institutions must maintain traceability and appropriate documentation while protecting information that identifies donors and patients.
A particularly important issue is the relationship between biological samples and their associated digital records.
Even if a biological sample is stored separately from a person's name, accompanying genetic or clinical information may still permit identification.
11. Biological security and research data governance
Federal Law No. 492-FZ of 30 December 2020, On Biological Safety in the Russian Federation, provides a broader framework for biological security.
It is relevant to biotechnology research involving:
Potentially dangerous biological agents.
Pathogenic microorganisms.
Biological materials.
High-containment laboratory activities.
Biological threats and associated information.
Biological safety and personal-data protection are related but different legal obligations.
For example, a research institution may properly anonymise a genomic dataset but still need to comply with separate biological-security requirements governing the underlying biological material.
Research organisations should therefore implement both information-security and biological-safety procedures.
12. Important case laws and judicial decisions
Russian biotechnology research data governance is a relatively developing legal field. There are limited published judicial decisions directly concerning modern genomic research databases and population-genetic research transfers.
Nevertheless, several judicial decisions provide important principles for interpreting medical confidentiality, personal-data protection and access to research-related medical information.
Case 1. Avilkina and Others v. Russia (2013)
European Court of Human Rights · Application No. 1585/09 · 6 June 2013
Facts of the case
The applicants were Jehovah's Witnesses who had received medical treatment in Russia.
Medical institutions disclosed their confidential medical information to the prosecutor's office in connection with investigations concerning refusals of blood transfusions.
The applicants argued that disclosure of their medical records violated their right to privacy.
Legal question
Whether disclosure of confidential medical information to a public authority without adequate safeguards violated Article 8 of the European Convention on Human Rights.
Decision
The European Court of Human Rights found a violation of Article 8.
The Court emphasised that medical information is an important aspect of private life and that confidentiality of health information requires strong protection.
It also criticised the absence of sufficiently precise limits and safeguards governing the prosecutor's access to medical records.
Relevance to biotechnology research
This judgment is highly relevant to genetic and biomedical research databases.
For example, a government authority cannot assume that it has unrestricted access to genomic research information merely because the information is held by a hospital or research institution.
Requests for access must have a lawful basis and appropriate safeguards.
HUDOC+1
Case 2. Constitutional Court of the Russian Federation, Judgment No. 1-P of 13 January 2020
Constitutional Court of Russia · 13 January 2020 · No. 1-P
Facts and legal issue
The Constitutional Court examined the legal uncertainty surrounding access to the medical records of a deceased patient.
The dispute concerned whether a spouse, close relatives or persons identified by the deceased patient in informed consent documentation could access medical information after the patient's death.
Decision
The Constitutional Court held that the existing legal framework was unconstitutional to the extent that it failed to provide sufficiently clear rules governing such access.
Pending legislative amendments, medical organisations were required, subject to the conditions identified by the Court, to provide the relevant persons with access to medical documents, unless the deceased patient had expressly prohibited disclosure during their lifetime.
Relevance to biotechnology research
This judgment has implications for:
Posthumous genetic research.
Family access to hereditary disease information.
Research involving deceased donors.
Inherited genetic conditions.
Medical-record retention.
Confidentiality of biological and clinical research records.
It demonstrates that the death of a research participant does not make medical confidentiality and access rights legally irrelevant.
ksrf.ru
Case 3. Z v. Finland (1997)
European Court of Human Rights · Application No. 22009/93 · 25 February 1997
Facts
The case involved the disclosure of confidential medical information concerning an individual's HIV status during criminal proceedings involving her husband.
Decision
The European Court emphasised the fundamental importance of protecting confidential medical information under Article 8.
It recognised that disclosure of medical information can have serious consequences for an individual's private and family life.
Relevance to biotechnology research
The reasoning is useful when considering sensitive research information concerning:
Genetic predispositions.
Hereditary disorders.
Infectious-disease susceptibility.
Reproductive health.
Molecular diagnoses.
A research institution should not disclose such information merely because disclosure might be scientifically useful.
HUDOC
Case 4. S. and Marper v. the United Kingdom (2008)
European Court of Human Rights · Applications Nos. 30562/04 and 30566/04 · 4 December 2008
Facts
The applicants challenged the indefinite retention of fingerprints, cellular samples and DNA profiles following criminal proceedings that did not result in convictions.
Decision
The Grand Chamber found that the blanket and indiscriminate retention arrangements violated Article 8.
Relevance to Russian biotechnology law
Although this case was decided against the United Kingdom, its reasoning provides an important comparative standard for considering:
Retention of genetic samples.
DNA databases.
Destruction of biological materials.
Genetic privacy.
Proportionality of long-term data storage.
It is not a Russian domestic precedent and should be used as comparative human-rights jurisprudence.
Important jurisdictional qualification: The ECHR judgments against Russia discussed above concern historical conduct. Russia ceased to be a party to the European Convention on 16 September 2022. These cases remain relevant as historical judicial authorities, but they do not establish continuing ECHR jurisdiction over later Russian conduct.
13. Regulatory authorities and institutional responsibilities
Several Russian institutions have responsibilities relevant to biotechnology research data governance.
| Authority | Principal responsibility |
|---|---|
| Roskomnadzor | Personal-data supervision and cross-border transfer regulation |
| Ministry of Health | Healthcare and biomedical research regulation |
| Ministry of Science and Higher Education | Scientific research policy |
| Rospotrebnadzor | Public health and relevant sanitary regulation |
| Government Interdepartmental Commission | Decisions on regulated international genetic-data transfers |
| Prosecutorial authorities | Supervision and legally authorised investigations |
The precise authority involved depends on the research activity and the type of information being processed.
14. Legal liabilities for biotechnology research data violations
Research institutions, biotechnology companies and responsible individuals may face legal consequences for violating applicable data-governance requirements.
A. Administrative liability
The Code of Administrative Offences of the Russian Federation contains provisions addressing violations of personal-data processing requirements.
Article 13.11 is particularly relevant.
Possible violations include:
Processing personal data without an appropriate legal basis.
Failure to comply with consent requirements.
Unlawful disclosure of confidential information.
Failure to comply with data-security requirements.
Violations of applicable data-localisation obligations.
B. Civil liability
Under the Russian Civil Code, individuals may seek legal remedies where unlawful processing or disclosure infringes their rights.
Potential remedies include compensation for moral harm where the relevant legal requirements are satisfied.
C. Criminal liability
Article 137 of the Criminal Code of the Russian Federation concerns unlawful collection or dissemination of information about a person's private life constituting personal or family secrets.
Article 272 may also become relevant where unlawful access to computer information satisfies its statutory requirements.
D. Liability under the Genetic Engineering Law
Federal Law No. 43-FZ of 2026 expressly introduced liability provisions into Article 12 of Federal Law No. 86-FZ.
Legal entities, officials and individuals, including foreign nationals and stateless persons, may incur liability for violating the statutory requirements concerning the transfer of human genetic data.
The precise consequences depend on the applicable administrative, civil or criminal provisions.
ГАРАНТ+1
15. Practical compliance framework for Russian biotechnology research institutions
A biotechnology institution conducting research in Russia should develop a comprehensive data-governance programme.
The following framework provides a practical compliance model.
Biotechnology research data governance framework
Research data identification
Identify whether the information contains personal, genetic, biometric, medical or population-level data.
Legal authorisation
Establish the legal basis for collection and processing, including applicable informed-consent requirements.
Data classification
Separate identifiable genetic information, pseudonymised datasets and anonymised research results.
Secure storage
Implement access controls, encryption, audit records and appropriate database-location arrangements.
International transfer assessment
Examine Articles 12 and 18 of Law No. 152-FZ and Articles 13.1 and 13.2 of Law No. 86-FZ.
Regulatory approval
Obtain the relevant Commission decision or complete the applicable notification procedure where required.
Retention and destruction
Establish lawful retention periods and procedures for destroying biological samples and research records.
Independent compliance monitoring
Conduct periodic legal, scientific and cybersecurity audits.
16. Major legal challenges
Despite the development of Russian biotechnology legislation, several important legal questions remain.
1. Genetic privacy versus scientific progress
Genomic datasets are valuable for understanding hereditary diseases and developing personalised medicine. However, extensive restrictions on access and transfers can complicate international scientific collaboration.
2. Anonymisation and re-identification
Genetic information can sometimes reveal individual identities even when conventional identifiers have been removed.
Consequently, anonymisation must be assessed in light of the actual risks of identification.
3. International research collaboration
Multinational pharmaceutical companies and universities may need to share research findings across national borders. The additional requirements of the 2026 genetic-data framework create important compliance considerations.
4. Artificial intelligence and genomic datasets
AI systems may process large genetic datasets to predict disease susceptibility, identify molecular patterns and develop personalised therapies.
Legal questions arise concerning the lawful reuse of datasets, automated analysis, data security and disclosure of predictive health information.
5. Secondary use of research data
A dataset initially collected for one research purpose may later be used for another scientific project.
Such secondary use must be examined against the original legal basis, consent terms and applicable statutory requirements.
6. Research participant rights
Research institutions must consider confidentiality, transparency, lawful processing and applicable rights to access or correct personal information.
7. Ownership and control of genetic information
There is an important distinction between ownership of a physical biological sample, intellectual-property rights in research discoveries and legal control over personal genetic information. These rights should not be treated as interchangeable.
17. Critical legal analysis
Russian biotechnology research data governance is developing through two complementary regulatory approaches.
The first approach focuses on individual rights, including privacy, medical confidentiality, informed consent and protection of personal information.
The second approach focuses on state regulation of human genetic data, particularly the transfer of population-level genetic and immunological research information.
The 2026 amendments to Federal Law No. 86-FZ are especially significant because they introduce a specialised legal regime for human genetic-data transfers rather than relying exclusively on general personal-data legislation.
The distinction between individual genetic information and population-level genetic research data is particularly important.
For example, a university conducting research involving several thousand participants may produce two different categories of information:
Individual-level genomic sequences.
Aggregated statistical findings concerning the research population.
These categories may be subject to different transfer procedures.
The new legislation also raises questions about the relationship between scientific openness, international collaboration and national biological security.
The long-term effectiveness of this framework will depend on clear implementing rules, transparent regulatory decisions, appropriate safeguards and effective judicial review.
18. Conclusion
Biotechnology Research Data Governance Law in Russia is based on a combination of constitutional protections, personal-data legislation, medical-confidentiality rules, genetic-engineering regulation and biological-security requirements.
The most significant legislative development is Federal Law No. 43-FZ of 20 February 2026, which introduced Articles 13.1 and 13.2 into Federal Law No. 86-FZ. Government Regulation No. 750 of 15 June 2026 subsequently established procedures for international transfers of human genetic information.
The judicial decisions in Avilkina and Others v. Russia and Constitutional Court Judgment No. 1-P of 13 January 2020 provide important principles concerning medical confidentiality and access to sensitive health information.
Ultimately, Russian biotechnology research data governance seeks to regulate the relationship between scientific freedom, personal privacy, medical confidentiality, genetic-data protection and national biological security.
19. Important legislation and judicial references for academic research
| Authority | Legal significance |
|---|---|
| Russian Constitution, Articles 23, 24, 41 and 44 | Privacy, information protection, healthcare and scientific freedom |
| Federal Law No. 152-FZ (2006) | Personal-data governance |
| Federal Law No. 86-FZ (1996) | Genetic-engineering and genetic-data transfer regulation |
| Federal Law No. 43-FZ (2026) | Special regulation of human genetic-data transfers |
| Government Regulation No. 750 (2026) | International genetic-data transfer procedures |
| Federal Law No. 323-FZ (2011) | Medical confidentiality |
| Federal Law No. 127-FZ (1996) | Scientific research |
| Avilkina and Others v. Russia (2013) | Confidentiality of medical information |
| Constitutional Court Judgment No. 1-P (2020) | Access to deceased patients' medical records |
| S. and Marper v. UK (2008) | Comparative DNA privacy and retention principles |
Primary legal research sources:
Federal Law No. 152-FZ – Personal Data Law.
Federal Law No. 43-FZ of 2026 – amendments to genetic-engineering legislation.
Government Regulation No. 750 of 2026.
Avilkina and Others v. Russia – ECHR judgment.
Constitutional Court Judgment No. 1-P of 2020.
Academic qualification: The 2026 genetic-data provisions are new, and the cited judgments do not directly decide disputes under those provisions. Their relevance is principally interpretative and comparative. For legal practice, the current consolidated Russian legislation and implementing regulations should be checked in their authoritative Russian-language versions.

comments